Close Menu
December 17, 2020
Sponsored by
Isoplexis

Walk-Away High-Plex Proteomics to Enable Accelerated Immune Medicine

Partner Webinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

IsoPlexis’ groundbreaking intracellular signaling omics application allows users to uniquely analyze signaling cascades of many phosphoproteins directly from each single cell, across thousands of single cells in parallel.

In this on-demand webinar, learn why it’s a critical tool for the characterization of cancer cell resistance pathways and the development of durable targeted therapies to overcome resistance.

Sponsored by

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Jan
28
Sponsored by
Sophia Genetics

This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources. 

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.